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Abstract
Background: Oligodeoxynucleotides containing unmethylated CpG motifs (CpG ODN) are
known to exert a strong adjuvant effect on Th1 immune responses. Although several genes have
been reported, no comprehensive study of the gene expression profiles in human cells after
stimulation with CpG ODN has been reported.
Results: This study was designed to identify a CpG-inducible gene cluster that potentially predicts
for the molecular mechanisms of clinical efficacy of CpG ODN, by determining mRNA expression
in human PBMC after stimulation with CpG ODN. PBMCs were obtained from the peripheral
blood of healthy volunteers and cultured in the presence or absence of CpG ODN 2006 for up to
24 hours. The mRNA expression profile was evaluated using a high-density oligonucleotide probe
array, GeneChip®. Using hierarchical clustering-analysis, out of a total of 10,000 genes we identified
a cluster containing 77 genes as having been up-regulated by CpG ODN. This cluster was further
divided into two sub-clusters by means of time-kinetics. (1) Inflammatory cytokines such as IL-6
and GM-CSF were up-regulated predominantly 3 to 6 hours after stimulation with CpG ODN,
presumably through activation of a transcription factor, NF-κB. (2) Interferon (IFN)-inducible anti-
viral proteins, including IFIT1, OAS1 and Mx1, and Th1 chemoattractant IP-10, were up-regulated
predominantly 6 to 24 hours after stimulation. Blocking with mAb against IFN-α/β receptor
strongly inhibited the induction of these IFN-inducible genes by CpG ODN.
Conclusion: This study provides new information regarding the possible immunomodulatory
effects of CpG ODN in vivo via an IFN-α/β receptor-mediated paracrine pathway.
Background
Several natural and synthetic compounds are known to
act as adjuvants that enhance immune responses when
administered with antigens, both in vitro and in vivo [1,2].
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immune responses and are used clinically to treat patients
with viral infections, malignant neoplasms, and recently
also those with allergic diseases [3,4]. BCG, a vaccine used
to protect against tuberculosis infection, can also trigger
an anti-tumor response when administered in vivo via
increased immunoglobulin synthesis and altered NK cell
activity [4]. The anti-tumor effect of BCG is attributed in
part to a DNA fraction named MY-1 found in BCG extracts
[5]. MY-1, which contains unmethylated CpG motifs,
enhances NK cell activity through induction of both type
I and type II interferons (IFNs) [4,5]. Synthetic oligodeox-
ynucleotides containing unmethylated CpG motifs (CpG
ODN) have also been shown to mimic the effect of bacte-
rial DNA in activating immune systems [6].
Recently, innate immunity has received attention not only
because it participates in the prevention of microbial
infection but also because it is capable of shifting host
immunity away from allergic immune responses (Th2)
toward non-allergic immune responses (Th1) [7,8]. Mol-
ecules that are highly conserved among species are
involved in the innate immune system as specific recep-
tors [7]. Human molecules responsible for innate immu-
nity are called Toll-like receptors (TLRs) [9], homologues
of Toll in Drosophila [10], which recognize pathogen-asso-
ciated molecular patterns (PAMPs) of microbial organ-
isms [7]. To date, 10 human TLRs have been identified
[11]. Among them, TLR9 recognizes the CpG motif from
bacterial DNA [12].
The fact that TLR9 is localized to the endocytic vesicles
suggests that CpG ODN enhances the immune response
of the host by acting as an adjuvant to ingested antigen in
antigen-presenting cells [13]. TLRs and IL-1R share similar
intracytoplasmic molecular associations [11]. TLRs initi-
ate signaling via sequential recruitment of myeloid differ-
entiation factor 88 (MyD88), IL-1R associated kinase
(IRAK) and tumor necrosis factor receptor-associated fac-
tor 6 (TRAF), which in turn activate downstream media-
tors such as mitogen-activated protein kinase (MAPK) and
transcription factors such as NF-κB, AP-1 and ATF-2 [11].
According to this signal transduction pathway, CpG ODN
would be expected to act as other PAMPs do [11,12].
However, administration of CpG ODN results in multiple
immunostimulatory effects in vivo without inducing seri-
ous endotoxin shock. This suggests that CpG ODN can be
used as a therapeutic adjuvant in several human diseases.
Recently, at least two phenotypes of CpG ODN have been
found [14–16]. A/D-type CpG ODNs promote produc-
tion of large amounts of type I IFN by plasmacytoid den-
dritic cells (PDC). In contrast, B/K-type CpG ODNs such
as CpG ODN 2006 strongly activate human B cells, pro-
mote their survival and up-regulate the expression of cos-
timulatory molecules on their cell surface. However, it is
known that administration of high doses of type I IFN
may directly induce various side effects, such as fever,
chills and depression [17]. Therefore, to investigate clini-
cal use of CpG ODN, we selected CpG ODN 2006, which
is B/K-type CpG ODN and so less likely to cause side
effects [6,15].
In this study, out of 10,000 genes we identified a gene
cluster containing 77 genes that were up-regulated by
CpG ODN. One sub-cluster included genes for inflamma-
tory cytokines and was up-regulated predominantly 3 to 6
hours after stimulation with CpG ODN. The second sub-
cluster included several genes for IFN-inducible anti-viral
and anti-tumor proteins and was up-regulated predomi-
nantly 6 to 24 hours after stimulation. These data suggest
a possible association between these molecules and the
immunomodulatory effects of CpG ODN in vivo.
Results
Identification of CpG ODN-inducible genes
Using hierarchical clustering-analysis of the gene expres-
sion profiles of approximately 10,000 genes, we identified
a cluster containing 77 genes which were up-regulated by
CpG ODN (Fig. 1). This cluster was further sub-divided
into two clusters on the basis of time-kinetics. Early-
response genes, including IL-6, lymphotoxin α (LTA) and
granulocyte-macrophage colony-stimulating factor (GM-
CSF, CSF2), were up-regulated predominantly 3 to 6
hours after stimulation with CpG ODN. In contrast, late-
response genes, including IFN-induced protein with
tetratricopeptide repeats 1 (IFIT1), IFIT2, 2',5'-oligoade-
nylate synthetase 1 (OAS1), OAS2, myxovirus (influenza
virus) resistance 1 (Mx1), Mx2 and IFN-γ inducible pro-
tein 10 (IP-10), were up-regulated predominantly 6 to 24
hours after stimulation with CpG ODN. Some CpG ODN-
inducible genes, especially such late-response genes as
IFIT1, OAS1 and IP-10, have been shown to be regulated
by type I IFN and/or type II IFNs [18]. However, mRNAs
for all type I IFNs were judged to be 'Absent' by Microarray
Suite software, which means that the mRNAs are below
the detection limit of the GeneChip® system (data not
shown).
Quantitative analysis of mRNA for CpG ODN-inducible 
genes
Up-regulation of the mRNA levels of five genes, IL-6, LTA,
OAS1, IFIT1 and IP-10, was further confirmed by real-
time PCR (Fig. 2). The magnitude of enhancement of the
mRNA for IL-6, LTA, OAS1, IFIT1 and IP-10 by CpG ODN
was 7-fold, 5-fold, 14-fold, 289-fold and 18-fold, respec-
tively. However, induction of inflammatory genes such as
IL-6 and GM-CSF by CpG ODN is very weak compared
with LPS (Fig. 3). Up-regulation of the mRNA levels of
CpG ODN-inducible genes, such as IP-10 and IL-6, wasPage 2 of 10
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CpG ODN mediated up-regulation of a gene cluster in PBMC. A gene cluster containing 77 genes was up-regulated 
more than two-fold in PBMC after stimulation with CpG ODN. Data were analyzed by applying a hierarchical-tree algorithm 
to the normalized intensity. The color code for the signal strength in the classification scheme is shown in the box on the left. 
Induced genes are indicated by shades of red; repressed genes are indicated by shades of blue. Exactly the same experiments 
were performed with PBMCs from three individual donors to confirm the reproducibility of the present experiments. All of 
these genes were consistently included in a CpG-inducible cluster in the same fashion even though cRNA elongation was not 
completed in a single experiment. * GenBank accession number
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BMC Immunology 2003, 4 http://www.biomedcentral.com/1471-2172/4/8CpG ODN mediated up-regulation of mRNA for IL-6, LTA, OAS1, IFIT1, IP-10 and IFN-α2Figure 2
CpG ODN mediated up-regulation of mRNA for IL-6, LTA, OAS1, IFIT1, IP-10 and IFN-α2. PBMC were incu-
bated in the presence or absence of 2 µg/ml CpG ODN 2006 for 6 hours. The mRNA levels of IL-6 (A), LTA (B), OAS1 (C), 
IFIT1 (D), IP-10 (E) and IFN-α2 (F) were determined by SYBR® green-based real-time quantitative RT-PCR. The results are 
shown as the mean ± SEM from four independent experiments. The copy number is expressed as the number of transcripts/ng 
of total RNA.Page 4 of 10
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BMC Immunology 2003, 4 http://www.biomedcentral.com/1471-2172/4/8scarcely induced by GpC control ODN, being less than
1:10 when compared to the enhancement by CpG ODN
2006 (data not shown). In addition, induction of a low
level of IFN-α was detectable by real-time PCR (Fig. 2).
Role of type I IFNs in the up-regulation of IFN-inducible 
genes by CpG ODN
To elucidate whether IFN-inducible genes such as IFIT1,
OAS1 and IP-10 were up-regulated directly by CpG ODN
or as a result of autocrine/paracrine pathways of IFNs,
blocking experiments were performed using anti-IFN
receptor mAbs. Up-regulation of mRNA for IFIT1 by IFN-
α2 and CpG ODN was significantly inhibited by the addi-
tion of anti-IFN-α/β receptor mAb (Fig. 4). With respect to
IP-10, mRNA expression was up-regulated by IFN-α2,
IFN-γ and CpG ODN. Induction of IP-10 by IFN-α2 or
IFN-γ was significantly inhibited by the addition of mAbs
specific for each IFN receptor (p < 0.05). The induction by
CpG ODN was significantly inhibited by anti-IFN-α/β
receptor mAb, whereas it was partially inhibited, though
not statistically significant, by anti-IFN-γ receptor mAb
(Fig. 4).
Moreover, we confirmed that up-regulation of mRNA for
OAS1, Mx1 and IFN regulatory factor 7 (IRF-7) by CpG
ODN was also strongly inhibited by the addition of anti-
IFN-α/β receptor mAb (Fig. 4C for OAS1; other data not
shown), whereas up-regulation of mRNA for IL-6 and LTA
by CpG ODN was not inhibited by the addition of these
anti-IFN receptor mAbs (data not shown). Moreover,
induction of each of IFIT1 and IP-10 by CpG ODN 2006
was not inhibited by the addition of these isotype control
mAbs (data not shown).
Discussion
Using the GeneChip® system, we identified a gene cluster
consisting of 88 probe sets in PBMC after stimulation with
CpG ODN. These genes are thought to be responsible for
the immunomodulatory effects of CpG ODN in vivo.
Among the 88 probe sets, 11 pairs of probe sets were
designed to recognize different parts of single genes. These
genes, including OAS1, IFN-induced protein 35 (IFI35),
IL-15Rα chain, STAT1, OAS2, IFIT1, IFN-stimulated gene
15 (ISG15), IFIT2, OASL, nuclear antigen Sp100 (SP100)
and LTA, were expressed at high levels. The fact that most
of these pair sets are located next- or very close- to each
other in this cluster after hierarchical clustering (Fig. 1)
indicated that the results of our experiment are highly
reproducible and reliable.
A recent study observed that human monocytes, NK cells
and T cells are not sensitive to CpG ODN because of their
poor expression of TLR9 [19]. However, they are activated
by CpG ODN-induced B cell- and PDC-derived cytokines
[19,20]. Since the focus of this study was to predict the
molecular mechanisms of clinically administered CpG
ODN, we selected a mixed population of cells (PBMC) to
allow for the effects of multiple cell interactions.
The gene sub-cluster that was predominantly up-regulated
at 3 to 6 hours after stimulation with CpG ODN contains
genes that encode inflammatory cytokines or chemokines
such as IL-6 and GM-CSF. Because the promotor regions
of these genes contain the NF-κB binding site, the up-reg-
ulation of these gene transcripts may be mediated by acti-
vation of NF-κB [21]. In addition, we report for the first
time that CpG ODN enhanced expression of the mRNA
for LTA in this sub-cluster. LTA is released from Th1 cells
and exerts proinflammatory effects [22]. However, induc-
tion of other inflammatory cytokines such as IL-6 by CpG
LPS mediated up-regulation of a gene cluster in PBMC, com-pared with CpG ODNFigur  3
LPS mediated up-regulation of a gene cluster in 
PBMC, compared with CpG ODN. A gene cluster con-
taining proinflammatory genes was up-regulated in PBMC 
after stimulation with LPS (100 ng/ml). For information 
regarding data analysis and color code, see Figure 1. * Gen-
Bank accession number
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BMC Immunology 2003, 4 http://www.biomedcentral.com/1471-2172/4/8Effects of blocking mAbs against IFN receptors on up-regulation of mRNA expression by CpG ODNFigure 4
Effects of blocking mAbs against IFN receptors on up-regulation of mRNA expression by CpG ODN. PBMC 
were stimulated with IFN-α2 (200 IU/ml), IFN-γ (100 IU/ml) or CpG ODN 2006 (2 µg/ml) in the presence or absence of 
blocking mAbs against IFN-α/β receptor or IFN-γ receptor for 6 hours. The mRNA levels of IFIT1 (A), IP-10 (B) and OAS1 (C) 
were determined by SYBR® green-based real-time quantitative RT-PCR. The results are shown as the mean ± SEM of three 
independent experiments and expressed as -fold increase above the mRNA level in the control cells. In this experiment, up-
regulation of IFIT1 and IP-10 by CpG ODN 2006 was not blocked by the addition of the isotype-matched control mAbs (data 
not shown). * p < 0.05 vs CpG ODN 2006 stimulated. NS: not significant.Page 6 of 10
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BMC Immunology 2003, 4 http://www.biomedcentral.com/1471-2172/4/8ODN seems to be very weak when compared to induction
by LPS (Fig. 3): the magnitude of enhancement of the
transcript for IL-6 was 242-fold and 7-fold by LPS and
CpG ODN 2006, respectively (data not shown). Moreo-
ver, induction of further inflammatory genes such as IL-
1β, TNFα and cyclooxygenase-2 (COX2), and neutrophil
chemoattractants such as growth-related oncogene 2
(GRO2) and GRO3 by LPS is of high magnitude and is
maintained for a long time (Fig. 3).
The majority of genes in the second sub-cluster (up-regu-
lated at 6 to 24 hours after stimulation with CpG ODN)
are known to be regulated by type I and/or type II IFNs.
These include: IFIT1, OAS1, Mx1, cig5, ISG15, IFI35, lym-
phocyte antigen 6 complex, locus E (LY6E), phospholipid
scramblase 1 (PLSCR1), SP100, metallothionein, TNF-
related apoptosis-inducing ligand (TRAIL, TNFSF10) and
IP-10 [18,23–28]. Interestingly, both the mRNA levels of
type I IFN measured by the GeneChip system and protein
levels of IFNs measured by ELISA were undetectably low
(data not shown). However, real-time quantitative RT-
PCR, the most sensitive way to measure mRNA levels, did
detect low levels of IFN-α2. To clarify whether or not the
enhancement of such mRNA expression is a direct effect of
CpG ODN or mediated by an IFN-autocrine/paracrine
pathway, we performed blocking experiments. As a result,
anti-IFN-α/β receptor mAb strongly inhibited the up-reg-
ulation of type I IFN-inducible genes such as IFIT1 and
OAS1, whereas anti-IFN-γ receptor mAb or isotype-
matched control mAbs did not elicit this response. Induc-
tion of IP-10, a type I/II IFN-inducible gene, by CpG ODN
2006 was also significantly inhibited by anti-IFN-α/β
receptor mAb. Induction of IP-10 was partially inhibited
by anti-IFN-γ receptor mAb, although this effect did not
reach statistical significance. Some publications suggest
that type I IFNs enhance production of IFN-γ by NK cells
and T cells [29,30]. Thus, some part of IP-10 induction by
CpG ODN may be regulated by type I IFN-induced IFN-γ.
In addition, our GeneChip® data indicate that CpG ODN
up-regulated the expression of IRF-7 (Fig. 1). With respect
to type I IFN synthesis, constitutive expression of IRF-3
along with inducible IRF-7 is known to play a key role
[31,32]. Furthermore, PDC – natural type I IFN producing
cells – are a very rare cell population (less than 0.1% of
PBMC) [33,34]. CpG ODN 2006 selectively stimulates the
early phase type I IFN induction in PDC but is unable to
initiate the IFN-α/β receptor-mediated autocrine feedback
loop [35]. Taken together, these results strongly suggest
that the effect of CpG ODN is at least in part mediated
through an IFN-α/β receptor-dependent paracrine path-
way. In contrast, NF-κB regulated genes, including IL-6,
were not affected by the IFN receptor mAbs. The signifi-
cant induction of IFN-inducible genes in correlation with
a low level of type I IFN suggests involvement of other
synergistic molecular mechanisms which have yet to be
elucidated.
Several groups have investigated the immunomodulatory
effects of CpG ODN in the clinical context including
chronic viral infection, malignant disease and allergy, and
initial results have been encouraging [36]. These results,
together with those of our study suggest a number of
genes may have possible roles in the clinical efficacy of
CpG ODN in the treatment of these diseases.
With respect to the treatment of chronic viral infections,
our study demonstrated that CpG ODN induces
production of mRNA for anti-viral proteins, including
IFIT1, OAS1, Mx1, ISG15 and TRAIL. IFIT1, a type I IFN-
inducible gene, was recently described to interact with
eukaryotic translation factor 3 (eIF-3), thus inhibiting
translation [37]. OAS1, a type I IFN-inducible gene, regu-
lates the RNase L dependent anti-viral defense pathway
[38]. Mx1, a type I IFN-inducible GTPase, has been shown
to inhibit replication of certain RNA viruses [39]. ISG15,
also known as an ubiquitin cross-reactive protein, is
known to be induced by type I IFNs and to form conju-
gates with intracellular proteins in a process analogous to
that for ubiquitin [40]. TRAIL is thought to be involved in
the selective killing of virus-infected cells and tumor cells
[27,28]. CpG ODN also induces mRNA for IP-10, which
recruits NK cells, and enhances the production of virus-
specific antibodies when administered as an adjuvant
with vaccine [36]. Up-regulation of these genes by CpG
ODN suggests potential prophylactic and therapeutic use
of CpG ODN in the treatment of viral infections.
In addition, CpG ODN is currently under trial in the treat-
ment of patients with allergic diseases through down-reg-
ulation of pre-existing Th2 type immune responses and
up-regulation of Th1 type immune responses [41–44].
Recently, it has become clear that type I IFNs are capable
of inducing Th1 type immune responses in humans but
not in mice [45]. The up-regulation of mRNA for IP-10 by
CpG ODN in our study supports the findings of previous
studies [20,46]. IP-10 is a natural ligand for CXCR3
expressed on Th1 cells and acts as an important regulator
in recruiting Th1 cells [47,48]. In addition, IP-10 acts as
an antagonist to CCR3 expressed on activated Th2 cells
and eosinophils [49]. These results suggest that type I IFNs
and IP-10 may have possible roles in the clinical efficacy
of CpG ODN in allergic diseases.
Conclusion
We applied the GeneChip® system to PBMC and identi-
fied, out of 10,000 genes, a gene cluster containing 77
genes which are up-regulated by CpG ODN 2006. This
cluster was further divided into two sub-clusters by means
of time-kinetics. One sub-cluster contains genes forPage 7 of 10
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BMC Immunology 2003, 4 http://www.biomedcentral.com/1471-2172/4/8inflammatory cytokines such as IL-6 and LTA, which were
up-regulated predominantly 3 to 6 hours after stimulation
with CpG ODN. However induction of these inflamma-
tory cytokines by CpG ODN is very weak when compared
with LPS, giving CpG ODN a favorable side effect profile.
The second cluster contains several genes for IFN-induci-
ble anti-viral proteins, including IFIT1, OAS1 and Mx1,
and Th1 chemoattractant IP-10, which were up-regulated
predominantly 6 to 24 hours after stimulation with CpG
ODN. Our experiments strongly suggest that induction of
these genes by CpG ODN was regulated through an IFN-
α/β receptor-dependent paracrine pathway involving a
sub-threshold level of type I IFN. This study provides new
information regarding the possible immunomodulatory
effects of CpG ODN in vivo via an IFN-α/β receptor-medi-
ated paracrine pathway.
Methods
Oligodeoxynucleotides
Phosphorothioate ODNs were synthesized at Operon
Technologies (Alameda, CA). The sequence of the CpG
ODN 2006 used in the present study was 5'-TCG TCG TTT
TGT CGT TTT GTC GTT-3' [6]. The sequence of the GpC
control ODN was 5'-TGC TGC TTT TGT GCT TTT GTG
CTT-3', which was modified by substitutions of GpC for
the CpG in CpG ODN 2006. ODNs were dissolved in
pyrogen-free double distilled water.
Preparation and cell culture
All human subjects in this study provided written
informed consent, which was approved by the Ethical
Review Board at National Children's Hospital in Tokyo,
Japan. Human peripheral blood mononuclear cells
(PBMC) were isolated by centrifugation on a Ficoll-Iso-
paque density gradient (d = 1.077 g/ml, Lymphoprep,
Nycomed, Oslo, Norway). After washing with PBS (Gibco
BRL, Grand Island, NY), the cells were suspended in
Iscove modified Dulbecco medium (IMDM; Gibco BRL)
supplemented with 100 U/ml penicillin and 100 µg/ml
streptomycin (Gibco BRL) at a cell density of 1 × 106 cells/
ml. PBMC were incubated in a 25 cm2 tissue culture flask
in the presence or absence of 2 µg/ml CpG ODN 2006 or
100 ng/ml LPS (Salmonella typhimurium; Sigma, St. Louis,
MO) for up to 24 hours. For real-time PCR analysis,
PBMC from four healthy volunteers were cultured in 6-
well plates in the presence or absence of 2 µg/ml CpG
ODN 2006 for 6 hours. As a control for a neutralization
study, PBMC were also incubated in the presence of 200
IU/ml IFN-α2 (Takeda Chemical Industries, Osaka,
Japan) or 100 IU/ml IFN-γ (Shionogi & Co, Ltd, Osaka,
Japan) without CpG ODN 2006 for 6 hours. In some
experiments, 10 µg/ml mouse anti-human IFN-α/β recep-
tor chain 2 (CD118) mAb (clone: MMHAR-2, IgG2a, PBL
Biomedical Laboratories, New Brunswick, NJ), 10 µg/ml
mouse anti-human IFN-γ receptor α-chain (CD119) mAb
(clone: GIR-208, IgG1, Pharmingen, San Diego, CA) or
isotype-matched control mAbs (IgG1: SouthernBiotech,
Birmingham, AL, IgG2a: eBioscience, San Diego, CA) were
added simultaneously with CpG ODN or IFNs through-
out the culture period.
GeneChip® expression analysis
Total RNA was extracted by RNeasy® (Qiagen, Hilden, Ger-
many) according to the manufacturer's instructions. Total
RNAs were pooled from three individual experiments for
each time point. Five micrograms of total RNA from each
sample (0, 3, 6 or 24 hours) were used to prepare cRNA.
Gene expression was analyzed with the GeneChip®
Human Genome U95Av2 probe array (Affymetrix, Santa
Clara, CA), which contains the oligonucleotide probe sets
for approximately 10,000 genes, according to the manu-
facturer's protocol (Expression Analysis Technical Man-
ual). Data analysis was performed with a Microarray Suite
version 4.0 software (Affymetrix) and a GeneSpring soft-
ware version 4.1 (Silicon Genetics, San Carlos, CA). To
normalize the staining intensity variations among chips,
the average difference values for all genes on a given chip
were divided by the median of all measurements on that
chip. Hierarchical-clustering analysis was performed
using a minimum distance value of 0.001, a separation
ratio of 0.5 and the standard definition of the correlation
distance.
Real-time quantitative RT-PCR
Primer sets for 7 genes, IL-6 (sense, 5'-CCA CAC AGA CAG
CCA CTC AC-3'; antisense, 5'-AGG TTG TTT TCT GCC
AGT GC-3'), LTA (sense, 5'-GGA GACC AGC TAT CCA
CCC AC-3'; antisense, 5'-TTC CTT CTT TGA AAG CTC
CGG-3'), IFIT1 (sense, 5'-GCC ATT TTC TTT GCT TCC
CCT A-3'; antisense, 5'-TGC CCT TTT GTA GCC TCC TTG-
3'), OAS1 (sense, 5'-CAT CCG CCT AGT CAA GCA CTG-
3'; antisense, 5'-CCA CCA CCC AAG TTT CCT GTA G-3'),
IP-10 (sense, 5'-CGC TGT ACC TGC ATC AGC ATT-3';
antisense, 5'-GCT CCC CTC TGG TTT TAA GGA G-3'),
IFN-α2 (sense, 5'-GGA TGA GAC CCT CCT AGA CAA AT-
3'; antisense, 5'-ATG ATT TCT GCT CTG ACA ACC TC-3')
and GAPDH (sense, 5'-GAA GGT GAA GGT CGG AGT C-
3'; antisense, 5'-GAA GAT GGT GAT GGG ATT TC-3') were
synthesized at Sawady Technology (Tokyo, Japan). These
molecules were chosen by means of an NF-κB-responsible
gene, a type I IFN-inducible gene, a type II IFN-inducible
gene, an IFN-α gene itself and a housekeeping gene,
respectively. Total RNA was analyzed after DNase I (Qia-
gen) digestion. Single-strand cDNA was synthesized with
SuperScript II reverse transcriptase (Gibco BRL). Real-time
quantitative RT-PCR was performed with a double-
stranded DNA-binding dye, SYBR® Green I, using an
Applied Biosystems 7700 Sequence Detection System
(Applied Biosystems, Foster City, CA) in 50 µL reactions
(25 µL 2 × SYBR® Green Master Mix (Applied Biosystems),Page 8 of 10
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BMC Immunology 2003, 4 http://www.biomedcentral.com/1471-2172/4/850 nM of each primer plus cDNA). The expression levels
of mRNA were normalized by the average expression of a
housekeeping gene (GAPDH). The copy number is
expressed as the number of transcripts/ng total RNA.
Statistical analysis
All data are presented as the mean ± SEM unless otherwise
noted. Differences between groups were analyzed using
the Mann-Whitney U-test and considered to be significant
if p < 0.05.
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